SEOUL : South Korea's Daewoong Pharmaceutical Co Ltd said on Tuesday it received Indian regulatory approval to test its anti-parasitic niclosamide drug to treat COVID-19 patients in an early-stage human trial.The phase 1 trial, approved by India's Central Drugs Standard Control Organisation (CDSCO), will involve around 30 healthy participants to test safety and kickstart this month, Daewoong said in a statement.The South Korean drugmaker is testing the drug in partnership with New Delhi-based Mankind Pharma Ltd, which will continue the second and third phases of trials in India on mild and severe coronavirus patients.Drugmakers worldwide are scrambling to develop treatments for the illness caused by the novel coronavirus, which has killed.